Etripamil NS 70 mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tachycardia, Supraventricular
Conditions
Tachycardia, Supraventricular, Paroxysmal Supraventricular Tachycardia
Trial Timeline
Jun 30, 2022 → Dec 10, 2024
NCT ID
NCT05410860About Etripamil NS 70 mg + Placebo
Etripamil NS 70 mg + Placebo is a phase 3 stage product being developed by Milestone Pharmaceuticals for Tachycardia, Supraventricular. The current trial status is completed. This product is registered under clinical trial identifier NCT05410860. Target conditions include Tachycardia, Supraventricular, Paroxysmal Supraventricular Tachycardia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05410860 | Phase 3 | Completed |
Competing Products
14 competing products in Tachycardia, Supraventricular
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ivabradine + Placebo | Amgen | Phase 3 | 76 |
| REGN7544 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| IgPro20 + Placebo | CSL | Phase 3 | 76 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Efgartigimod + Placebo | Argenx | Phase 2 | 49 |
| Northera (Droxidopa) + Placebo + Northera (Droxidopa) + Placebo | Lundbeck | Phase 2 | 49 |
| Etripamil + Placebo + Etripamil Test Dose | Medpace | Phase 3 | 74 |
| Etripamil NS 70 mg | Medpace | Phase 3 | 74 |
| Etripamil + Placebo | Medpace | Phase 2 | 49 |
| IVIG + Albumin | Grifols | Phase 1/2 | 38 |
| SGT-501 | Solid Biosciences | Phase 1 | 25 |
| Etripamil NS | Milestone Pharmaceuticals | Phase 3 | 69 |
| Etripamil NS | Milestone Pharmaceuticals | Phase 2 | 44 |
| Etripamil NS 70 mg | Milestone Pharmaceuticals | Phase 3 | 69 |